Mon panier

Human ROR1 (30-305) Protein, His Tag (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
ETA of in-stock products:2 business days
Total des articles Montant du produit0

Détails du produit

  • Synonym

    ROR1, NTRKR1

  • Source

    Human ROR1 (30-305) Protein, His Tag (RO1-H52H3) is expressed from human 293 cells (HEK293). It contains AA Gln 30 - Asp 305 (Accession # Q01973-1).

    Predicted N-terminus: Gln 30

    Request for sequence
  • Molecular Characterization

    ROR1 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 32.7 kDa. The protein migrates as 42-50 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    ROR1 SDS-PAGE

    Human ROR1 (30-305) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    ROR1 SEC-MALS

    The purity of Human ROR1 (30-305) Protein, His Tag (Cat. No. RO1-H52H3) is more than 90% and the molecular weight of this protein is around 35-50 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     ROR1 ELISA

    Immobilized Human ROR1 (30-305) Protein, His Tag (Cat. No. RO1-H52H3) at 1 μg/mL (100 μL/well) can bind Human Anti-ROR1 Antibody with a linear range of 0.03-1 ng/mL (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Tyrosine-protein kinase transmembrane receptor ROR1 is also known as Neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), which belongs to the protein kinase superfamily or tyr protein kinase family or ROR subfamily. ROR1 contains 1 FZ (frizzled) domain, 1 Ig-like C2-type (immunoglobulin-like) domain, 1 kringle domain, 1 protein kinase domain. ROR1 is expressed at high levels during early embryonic development. The expression levels drop strongly around day 16 and there are only very low levels in adult tissues. Isoform Short is strongly expressed in fetal and adult CNS and in a variety of human cancers, including those originating from CNS or PNS neuroectoderm. ROR1 could interact with casein kinase 1 epsilon (CK1ε) to activate phosphoinositide 3-kinase-mediated AKT phosphorylation and cAMP-response-element-binding protein (CREB), which was associated with enhanced tumor-cell growth.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Inactive tyrosine-protein kinase transmembrane receptor ROR1

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    22 Détails

  • Étape de développement la plus élevée:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte